The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157 penis enlargement: What the evidence and real world experience actually show On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare